J. Lipid Res. Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on June 1, 2005

Papers In Press, published online ahead of print March 16, 2005
J. Lipid Res., doi:10.1194/jlr.M400426-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M400426-JLR200v1
46/6/1295    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coort, S. L. M.
Right arrow Articles by Luiken, J. J. F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coort, S. L. M.
Right arrow Articles by Luiken, J. J. F. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on October 27, 2004
Revised on March 3, 2005
Accepted on March 10, 2005

Divergent effects of rosiglitazone on plasmalemmal fatty acid uptake capacity and transporter proteins in adipose and in muscle tissues of obese Zucker rats

Susan L. M. Coort, Will A. Coumans, Arend Bonen, Ger J. van der Vusse, Jan F. C. Glatz, and Joost J. F. P. Luiken

Department of Molecular Genetics, Maastricht University, Maastricht 6200 MD

Corresponding Author: s.coort{at}gen.unimaas.nl

Thiazolidinediones (TZDs) increase tissue insulin sensitivity in type-2 diabetes, and enhance long-chain fatty acid (FA) deposition in adipocytes. Here, we hypothesize that, in adipose tissue, skeletal muscle and heart, alterations in the capacity to take up FA and in the total and plasmalemmal contents of membrane-associated FA transport proteins (FAT/CD36, FATP1 and FABPpm) are involved in the insulin sensitizing effect of TZDs. As a model we used insulin-resistant, obese Zucker rats, orally treated for 16 days with 5 mg rosiglitazone (Rgz)/kg body mass per day. In adipose tissue from Rgz-treated rats, FA uptake capacity increased by 2.0-fold, coinciding with increased total tissue contents of FAT/CD36 (2.3-fold) and FATP1 (1.7-fold), but not of FABPpm, whereas changes at the level of the plasmalemma were only observed for FAT/CD36 (increase of 1.7-fold). The increase in FA uptake capacity of adipose tissue was associated with a decline in plasma FA (-53%) and triacylglycerols (TAG, -56%), suggesting that Rgz-treatment enhanced plasma FA extraction by adipocytes. In obese hearts, Rgz-treatment had no effect on the FA transport system, yet the total TAG content decreased by 36%, suggesting enhanced cardiac insulin sensitivity. In skeletal muscle the FA transport system also remained unaltered, although, the overall TAG content in skeletal muscle did not decline. However, cytoplasmic adipose-type FABP content increased in skeletal muscle, suggesting that increased deposition of TAG in muscular adipose tissue masks the decline of TAG in muscle fibers. In conclusion, our study implicates FAT/CD36 in the mechanism by which rosiglitazone, in obese Zucker rats, redirects the FA flux from muscle towards adipose tissue, causing plasma FA and TAG concentrations to decline, and reducing intramyocellular lipid overload.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.